Sign in
Enrolling by invitationNo phase

LIMA1 Immunohistochemistry and Depth of Invasion as Prognostic Biomarkers in Oral Squamous Cell Carcinoma

Key facts

Who runs it
Turku University Hospital
Where
Finland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Enrolling by invitation
People taking part
140 people, planned
Started
19 Oct 2026
Expected to end
31 Dec 2032
Type of study
Observational
Record updated
12 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age ≥18 years
  • Newly diagnosed oral squamous cell carcinoma (OSCC)
  • Curative-intent primary surgical treatment planned for OSCC
  • Written informed consent for participation in the study
  • Sufficient surgically resected tumor tissue available for study analyses

Who cannot take part

  • Patient is receiving palliative rather than curative-intent treatment
  • Insufficient tumor tissue in the surgical resection specimen for the planned study analyses
  • Age <18 years
  • Patient does not provide written informed consent

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This prospective, multicenter observational study evaluates LIMA1 immunohistochemistry (IHC) and histological depth of invasion (DOI) as prognostic biomarkers in adult patients with newly diagnosed oral squamous cell carcinoma (OSCC) undergoing curative-intent primary surgical treatment.

Read full original descriptionShow less

LIMA1 expression will be assessed in surgically resected primary tumor specimens by immunohistochemistry using antibody clone Thab2c, developed by Thestra Ltd and raised against LIMA1-alpha. LIMA1 IHC staining will be scored using a prespecified four-level scoring system from 0 to 3 and classified as LIMA1-low (scores 0-1) or LIMA1-high (scores 2-3). Histological DOI will be determined from hematoxylin and eosin (H\&E)-stained primary tumor specimens and classified as DOI-low (<5 mm) or DOI-high (≥5 mm).

The primary objective is to determine whether adding LIMA1 IHC to DOI improves the identification of patients with a favorable disease-specific outcome after surgery alone compared with DOI alone. The primary analysis will focus on patients treated with curative-intent surgery without adjuvant radiotherapy or chemoradiotherapy. A disease-specific OSCC event is defined as local recurrence, new regional lymph node metastasis, distant metastasis, or death attributable to the index OSCC.

Clinical outcomes will be assessed at 2, 3, and 5 years. The study will also evaluate overall survival, OSCC recurrence-free survival, individual disease-specific OSCC events, and the technical evaluability and interobserver reproducibility of the Thab2c LIMA1 IHC assay. Study biomarker results will not affect patient treatment.

The group in the trial

  • Patients With Oral Squamous Cell Carcinoma

    Adult patients with newly diagnosed oral squamous cell carcinoma (OSCC) undergoing curative-intent primary surgical treatment. LIMA1 expression and histological depth of invasion (DOI) will be assessed in primary tumor specimens. Patients will be classified according to prespecified LIMA1 IHC and DOI categories for prognostic analyses. Study biomarker results will not influence treatment decisions.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prospective Clinical Validation of LIMA1 Immunohistochemistry and Depth of Invasion as Prognostic Biomarkers in Oral Squamous Cell Carcinoma
Record updated
12 November 2026